MATTHEW BOGOYAS: Open Payments
NPI 1336508423 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$202,282 in 277 payments from 11 companies in 2025. Trend: 2023 $81,493 · 2024 $185,707 · 2025 $202,282
Speaker / faculty: $144,556Honoraria: $29,200Consulting: $13,688Travel & lodging: $8,930Food & beverage: $5,691Education: $216
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 86 | $72,264 |
| Teva Pharmaceuticals USA, Inc. | 48 | $39,393 |
| Neurocrine BioSciences, Inc. | 40 | $37,352 |
| Axsome Therapeutics, Inc. | 41 | $32,440 |
| Otsuka America Pharmaceutical, Inc. | 48 | $17,907 |
| Janssen Scientific Affairs, LLC | 1 | $2,725 |
| Janssen Pharmaceuticals, Inc | 7 | $83 |
| Alkermes, Inc. | 3 | $64 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: COBENFY, INGREZZA, Auvelity, UZEDY, ABILIFY MAINTENA, AUSTEDO XR, SPRAVATO, REXULTI.
Industry payments across WA — which companies pay providers there.
